Abstract

BackgroundMyostatin (Mstn) is a negative regulator of muscle growth whose inhibition promotes muscle growth and regeneration. Dystrophin-deficient mdx mice in which myostatin is knocked out or inhibited postnatally have a less severe phenotype with greater total mass and strength and less fibrosis and fatty replacement of muscles than mdx mice with wild-type myostatin expression. Dogs with golden retriever muscular dystrophy (GRMD) have previously been noted to have increased muscle mass and reduced fibrosis after systemic postnatal myostatin inhibition. Based partly on these results, myostatin inhibitors are in development for use in human muscular dystrophies. However, persisting concerns regarding the effects of long-term and profound myostatin inhibition will not be easily or imminently answered in clinical trials.MethodsTo address these concerns, we developed a canine (GRippet) model by crossbreeding dystrophin-deficient GRMD dogs with Mstn-heterozygous (Mstn+/−) whippets. A total of four GRippets (dystrophic and Mstn+/−), three GRMD (dystrophic and Mstn wild-type) dogs, and three non-dystrophic controls from two litters were evaluated.ResultsMyostatin messenger ribonucleic acid (mRNA) and protein levels were downregulated in both GRMD and GRippet dogs. GRippets had more severe postural changes and larger (more restricted) maximal joint flexion angles, apparently due to further exaggeration of disproportionate effects on muscle size. Flexors such as the cranial sartorius were more hypertrophied on magnetic resonance imaging (MRI) in the GRippets, while extensors, including the quadriceps femoris, underwent greater atrophy. Myostatin protein levels negatively correlated with relative cranial sartorius muscle cross-sectional area on MRI, supporting a role in disproportionate muscle size. Activin receptor type IIB (ActRIIB) expression was higher in dystrophic versus control dogs, consistent with physiologic feedback between myostatin and ActRIIB. However, there was no differential expression between GRMD and GRippet dogs. Satellite cell exhaustion was not observed in GRippets up to 3 years of age.ConclusionsPartial myostatin loss may exaggerate selective muscle hypertrophy or atrophy/hypoplasia in GRMD dogs and worsen contractures. While muscle imbalance is not a feature of myostatin inhibition in mdx mice, findings in a larger animal model could translate to human experience with myostatin inhibitors.Electronic supplementary materialThe online version of this article (doi:10.1186/s13395-016-0085-7) contains supplementary material, which is available to authorized users.

Highlights

  • Myostatin (Mstn) is a negative regulator of muscle growth whose inhibition promotes muscle growth and regeneration

  • Cranial sartorius circumference We have previously shown that the cranial sartorius (CS) muscle undergoes dramatic hypertrophy in golden retriever muscular dystrophy (GRMD) dogs and that this hypertrophy tracks with postural abnormalities [44]

  • Myostatin messenger ribonucleic acid (mRNA) and protein levels were down regulated in GRMD dogs independent of myostatin status, suggesting an inherent feedback mechanism intended to promote muscle regeneration

Read more

Summary

Introduction

Myostatin (Mstn) is a negative regulator of muscle growth whose inhibition promotes muscle growth and regeneration. Dogs with golden retriever muscular dystrophy (GRMD) have previously been noted to have increased muscle mass and reduced fibrosis after systemic postnatal myostatin inhibition. Dystrophin-deficient mdx mice in which myostatin is knocked out (Mstn−/−) [13] or inhibited postnatally [14, 15] have a less severe phenotype with greater absolute force and less fibrosis of individual muscles. Based on these findings, there has been increasing interest in treatments to inhibit myostatin and promote muscle growth [16, 17]. Additional questions have been raised about potential exhaustion of the pool of muscle progenitor cells (i.e., satellite cells) undergoing multiple divisions in the absence of myostatin in muscular dystrophy [24]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call